LENZ Therapeutics (LENZ) Depreciation & Amortization (CF) (2022 - 2025)
LENZ Therapeutics (LENZ) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $107000.0 as the latest value for Q4 2025.
- Quarterly Depreciation & Amortization (CF) rose 328.0% to $107000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $287000.0 through Dec 2025, up 394.83% year-over-year, with the annual reading at $287000.0 for FY2025, 394.83% up from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 was $107000.0 at LENZ Therapeutics, down from $125000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $800000.0 in Q2 2023, with the low at $3000.0 in Q1 2023.
- Average Depreciation & Amortization (CF) over 4 years is $286666.7, with a median of $107000.0 recorded in 2025.
- The sharpest move saw Depreciation & Amortization (CF) crashed 99.32% in 2023, then soared 1150.0% in 2025.
- Over 4 years, Depreciation & Amortization (CF) stood at $682000.0 in 2022, then increased by 17.3% to $800000.0 in 2023, then tumbled by 96.88% to $25000.0 in 2024, then skyrocketed by 328.0% to $107000.0 in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $107000.0, $125000.0, and $19000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.